## RESPONSE UNDER 37 C.F.R. § 1.116 EXPEDITED PROCEDURE – Art Unit 1651

Attorney Docket No. 54704.8018.US00

## Amendm nts

A list of pending claims:

1-13 (canceled).

14 (previously canceled).

15 (canceled).

16 (currently amended). A composition for use as a standardized measure of apoptosis in a test tissue sample from a subject, the composition comprising:

at least one segment of a naturally occurring tissue that-has been subjected to a treatment that reproducibly results in a predetermined, measurable amount of apoptosis in the segment;

at least a negative control segment of a tissue which has not been subjected to the treatment and at least a positive control segment of the tissue which has been subjected to a level of the treatment that reproducibly results in a maximum amount of apoptosis obtainable in the segment as a result of the treatment; and

The composition of claim 15, further comprising one or more intermediate control segments of the tissue which have been subjected to a level of the treatment that reproducibly results in a predetermined amount of apoptosis intermediate between that of the negative control segment and that of the positive control segment.

17-18 (canceled).

19 (currently amended). A kit for evaluating apoptosis in a test sample of tissue, the kit comprising:

a container containing at least one segment of a naturally occurring tissue that has been subjected to a treatment that reproducibly results in a predetermined, measurable amount of apoptosis in the segment, and

## RESPONSE UNDER 37 C.F.R. § 1.116

EXPEDITED PROCEDURE – Art Unit 1651 Attorney Docket No. 54704.8018.US00

instructions for use of the segment in evaluating the apoptosis in the test sample of tissue;

at least a negative control segment of a tissue which has not been subjected to the treatment and at least a positive control segment of the tissue which has been subjected to a level of the treatment that reproducibly results in a maximum amount of apoptosis obtainable in the segment as a result of the treatment; and

The kit of claim 18, further comprising one or more intermediate control segments of the tissue which have been subjected to a level of the treatment that reproducibly results in a predetermined amount of apoptosis intermediate between that of the negative control segment and that of the positive control segment.

20-22 (canceled).

23-25 (previously canceled).

26-29 (canceled).